Bosutinib, a Src/c-Abl inhibitor, reduced the misfolded mutant SOD1 protein levels, improved the expression of mitochondrial genes, and modestly extended G93A ALS mouse model survival [40]. Here, ABL1 is linked to amyotrophic lateral sclerosis.